Accelerating Australian vaccine and infectious disease innovation for global impact.
Expressions of Interest - CLOSED
Next intake: Q3 2026
Biointelect Venturer accelerates infectious disease innovation
Biointelect Venturer is a virtual incubator giving promising Australian scientific innovators, the funding, strategic guidance, networks, and resources to advance important early-stage innovations for the prevention of infectious disease from concept to commercial and investment readiness.
The incubator supports SMEs to accelerate the development of breakthrough technologies for the prevention of infectious diseases with a clear commercialisation pathway and potential to deliver meaningful impact on the infectious disease prevention landscape, including prophylactic vaccines, immunotherapies and related technologies.
Our Mission
To nurture promising early-stage SMEs by providing the funding and access to expertise and resources to accelerate development and commercialisation of breakthrough innovations for the prevention of infectious disease.
Our vision
To be a world-leading catalyst for transformative Australian vaccine and infectious disease innovation for global health impact.
Funded by the Australian Government, under the Medical Research Future Fund (MRFF) 2024 BioMedTech Incubator Grant Opportunity, Biointelect Venturer supports Australian small-to-medium enterprises (SMEs) by offering comprehensive, tailored support, including:
- Funding – catalytic non-dilutive funding to support activities to progress promising science toward investment readiness.
- Expert guidance and training – building and enhancing development and commercialisation capabilities
- National and international networks – connections across industry, academia, government, service providers and investors to drive collaboration and co-development.
- Market orientation – ensuring that innovations are viable, scalable, and aligned with both commercial opportunity and public health need.
Together, these resources empower Australian innovators to accelerate vaccine and infectious disease breakthroughs, to attract follow-on funding and investment.
Cohort enrolment
The 2025 EOI period is now closed.
- All submitted applications are currently undergoing eligibility review and evaluation. Applicants will be notified of outcomes in February 2026.
- Next intake expected in Q3 2026.
Sign up to receive the latest information about the incubator, and be part of the Australian Vaccine Network.
